Evidence mapPaperPMID 41111503Full record

ReviewFrontiers in pharmacology2025

Plant-derived natural products targeting inflammation in treatment of atherosclerosis.

Zhen Hua, Xiaojie Wang, Le-Le Qin, Kun-Peng Zhu, De-Ye Li, Xin-Yue Zhang, Lei Zhang, Feng-Ting Zhai

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhen HuaDepartment of Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Xiaojie WangCollege of Traditional Chinese medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Le-Le QinFirst School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Kun-Peng ZhuFirst School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
De-Ye LiFirst School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Xin-Yue ZhangFirst School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Lei ZhangDepartment of Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Feng-Ting ZhaiDepartment of Gynaecology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis (AS) is a complex and chronic inflammatory vascular disease, and it's also the pathological basis of various diseases such as coronary heart disease. Owing to their advantages such as multiple targets and rich diversity, Plant-Derived natural products with abundant resources will become an important source of anti-AS drugs. Herein, we explored the intricate association between inflammation and AS, focusing on plant-derived natural products that specifically target inflammation for the treatment of AS. This review systematically analyzes 10 plant species, focusing on 23 high-potential metabolites including Tanshinone IIA, Berberine, and Ginsenoside Rb1 et al. We found that natural products with anti-AS properties are primarily derived from plants belonging to the families Araliaceae, Umbelliferae, Fabaceae, and Lamiaceae. The chemical structures of these natural products mainly consist of flavonoids, alkaloids, saponins, and polysaccharides, among others. This suggests that natural products with different structural types can exhibit anti-AS activities, with flavonoids, alkaloids, and saponins showing greater potential. Major anti-inflammatory pathways center on NF-κB/NLRP3 inflammasome inhibition (e.g., Tan IIA, Salidroside), ROS scavenging (e.g., Danshensu, Rosmarinic acid), and endothelial protection (e.g., Astragaloside, Puerarin), while highlighting NLRP3 inflammasome inhibition and gut-microbiota modulation as emerging therapeutic avenues. These will actively promote the clinical application and industrial production of Plant Derived natural products, thereby developing anti AS drugs with excellent efficacy and reduced adverse reactions. We hope that this comprehensive review will provide valuable insights into the potential and pharmacological mechanisms of current natural medicines, thereby offering support for future drug discoveries.

Indexed as

atherosclerosisChinese herbal medicineinflammationplant-derived natural productstraditional Chinese medicine

Identifiers

PMID41111503
PMCPMC12528052

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.